Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer

Christophe Massard, Michael S. Gordon, Sunil Sharma, Saeed Rafii, Zev A. Wainberg, Jason Luke, Tyler J. Curiel, Gerardo Colon-Otero, Omid Hamid, Rachel E. Sanborn, Peter H. O'Donnell, Alexandra Drakaki, Winston Tan, John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. Blake-Haskins, Ashok Gupta, Neil H. Segal

Research output: Contribution to journal › Article › peer-review

539 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences